|Home | About | Journals | Submit | Contact Us | Français|
Carboplatin is a less toxic analog of cisplatin, but carboplatin also has side effects, including bone marrow suppression. Therefore, to improve the capacity of the anticancer activity of carboplatin, we investigated whether combined treatment with carboplatin and thioridazine, which has antipsychotic and anticancer activities, has a synergistic effect on apoptosis. Combined treatment with carboplatin and thioridazine markedly induced caspase-mediated apoptosis in head and neck squamous cell carcinoma (AMC-HN4) cells. Combined treatment with carboplatin and thioridazine induced downregulation of Mcl-1 and c-FLIP expression. Ectopic expression of Mcl-1 and c-FLIP inhibited carboplatin plus thioridazine-induced apoptosis. We found that augmentation of proteasome activity had a critical role in downregulation of Mcl-1 and c-FLIP expression at the post-translational level in carboplatin plus thioridazine-treated cells. Furthermore, carboplatin plus thioridazine induced upregulation of the expression of proteasome subunit alpha 5 (PSMA5) through mitochondrial reactive oxygen species (ROS)-dependent nuclear factor E2-related factor 2 (Nrf2) activation. In addition, combined treatment with carboplatin and thioridazine markedly induced apoptosis in human breast carcinoma (MDA-MB231) and glioma (U87MG) cells, but not in human normal mesangial cells and normal human umbilical vein cells (EA.hy926). Collectively, our study demonstrates that combined treatment with carboplatin and thioridazine induces apoptosis through proteasomal degradation of Mcl-1 and c-FLIP by upregulation of Nrf2-dependent PSMA5 expression.
Carboplatin is an analog of cisplatin that binds to DNA and then inhibits replication and transcription, resulting in cell death.1 Carboplatin has less gastrointestinal toxicity, nephrotoxicity, and neurotoxicity compared with cisplatin.2 It is an effective chemotherapeutic drug in head and neck cancer,3 endometrial cancer,4 and small cell lung cancer.5 However, the anticancer effect of carboplatin is inhibited by intrinsic or acquired drug resistance. Several molecular mechanisms of carboplatin resistance have been discovered, including (1) decreased tumor blood flow and drug uptake, (2) increased drug efflux and detoxification, (3) increased DNA repair and tolerance of DNA damage, (4) downregulation of pro-apoptotic proteins and upregulation of antiapoptotic proteins, and (5) altered cell signaling pathways.6 Combination therapy with other anticancer drugs could improve the anticancer effect and reduce the drug resistance of carboplatin.
Thioridazine (10-[2-(1-methyl-2-piperidyl) ethyl]-2-(methylthio) phenothiazine) is an antipsychotic7, 8 and anti-microbial drug.9, 10 In addition, thioridazine also has anticancer activity through induction of apoptosis in multiple cancer cells11, 12, 13, 14, 15, 16 and inhibition of angiogenesis17, 18 and metastasis.19, 20 Furthermore, thioridazine overcomes drug resistance through inhibition of P-glycoprotein.21, 22 As high concentrations of thioridazine cause side effects, such as dysrhythmia and sudden death,23, 24 strategies against combined treatment with low concentrations of thioridazine plus anticancer drugs have been investigated. For example, combined treatment with thioridazine and TRAIL induced apoptosis in human renal carcinoma Caki cells by downregulating antiapoptotic proteins.25 In addition, treatment with thioridazine plus doxorubicin using nanoparticles inhibited growth in breast cancer cells.26
Degradation of proteins is mainly regulated by the ubiquitin-proteasome pathway (UPP). The 26S proteasome is a multi-protein complex and is composed of the 20S catalytic proteasome and 19S regulatory subunits. The increase of proteasome activity is related to upregulation of the expression of the proteasome subunit.27 De novo synthesis of the proteasome subunit is tightly regulated by nuclear factor E2-related factor 2 (Nrf2).28 In the absence of stimuli, Keap-1 retains Nrf2 in the cytoplasm, resulting in inhibition of transcriptional activity. However, oxidative stress modifies the cysteine residue of Keap-1, and then, Nrf2 is released.29 The translocation of Nrf2 from the cytosol to the nucleus induces gene expression by binding to the antioxidant response element (ARE).29
In our study, we investigated whether combined treatment with carboplatin and thioridazine induces apoptosis and examined the molecular mechanisms of apoptosis in head and neck squamous cell carcinoma (AMC-HN4) cells.
To determine whether there is an apoptotic effect between carboplatin and thioridazine, AMC-HN4 cells were treated with carboplatin in the absence or presence of thioridazine. Carboplatin alone and thioridazine alone had no effect on apoptosis, but combined treatment with carboplatin and thioridazine induced apoptosis and PARP cleavage, which is a substrate of caspase-3 (Figure 1a). Next, we investigated whether combined treatment with carboplatin and thioridazine had synergistic effects. Isobologram analysis suggested that carboplatin plus thioridazine had synergistic effects (Figure 1b). Furthermore, carboplatin plus thioridazine increased chromatin damage in the nucleus (Figure 1c) and cytoplasmic histone-associated DNA fragments (Figure 1d). In addition, we examined whether caspase activation is involved in apoptosis in carboplatin plus thioridazine-treated cells. Combined treatment markedly increases caspase-3 activation (Figure 1e), and a pan-caspase inhibitor (z-VAD) blocked carboplatin and thioridazine-induced apoptosis as well as PARP cleavage (Figure 1f). To further determine the molecular mechanisms underlying carboplatin plus thioridazine-induced apoptosis, we examined the modulation of the expression of apoptosis-related proteins. Both c-FLIP and Mcl-1 expression were downregulated (Figure 1g). These results indicated that combined treatment with carboplatin and thioridazine induces caspase-mediated apoptosis and downregulated expression of c-FLIP and Mcl-1.
To evaluate the functional importance of the c-FLIP and Mcl-1 proteins in carboplatin plus thioridazine-induced apoptosis, we used c-FLIP- and Mcl-1-overexpressing cells. Overexpression of c-FLIP or Mcl-1 markedly inhibits carboplatin plus thioridazine-induced apoptosis and PARP cleavage (Figure 2a and b). Combined treatment with carboplatin and thioridazine gradually decreased c-FLIP and Mcl-1 expression over 6h (Figure 2c), but the mRNA expression of both was not changed (Figure 2d). Therefore, we examined whether carboplatin plus thioridazine modulates the protein stability of c-FLIP and Mcl-1. Cells were treated with cycloheximide (CHX), an inhibitor of de novo protein synthesis, in the presence or absence of carboplatin plus thioridazine. As shown in Figure 2e, CHX in the presence of carboplatin plus thioridazine rapidly reduced expression of c-FLIP and Mcl-1 compared with CHX alone. These data suggested that the combined treatment of carboplatin and thioridazine induces downregulation of c-FLIP and Mcl-1 expression at the post-translational level and that downregulation of c-FLIP and Mcl-1 expression has a critical role in carboplatin plus thioridazine-induced cell death.
Downregulation of c-FLIP and Mcl-1 protein expression is mainly regulated by the activation of the Ubiquitin-proteasome pathway (UPP).30, 31 As shown in Figure 3a, proteasome inhibitors (MG132 and lactacystine) inhibited carboplatin plus thioridazine-mediated downregulation of c-FLIP and Mcl-1 protein expression, and proteasome activity was markedly increased by the combined treatment with carboplatin and thioridazine (Figure 3b). Therefore, we investigated whether carboplatin plus thioridazine modulates the expression of the key proteasome subunit, 20S proteasome subunit alpha type 5 (PSMA5). PSMA5 expression is markedly upregulated by the carboplatin plus thioridazine treatment (Figure 3c). Next, we examined whether upregulation of PSMA5 expression has a critical role in carboplatin plus thioridazine-mediated apoptosis. As shown in Figure 3d, downregulation of PSMA5 by siRNA inhibited apoptosis and cleavage of PARP in carboplatin plus thioridazine-treated cells. In addition, the combined treatment-mediated downregulation of c-FLIP and Mcl-1 was recovered by knockdown of PSMA5 (Figure 3d). The combined treatment with carboplatin and thioridazine upregulated the expression of PSMA5 at the protein and mRNA level in a time-dependent manner (Figure 3e). The PSMA5 promoter activity was also increased with the carboplatin plus thioridazine treatment (Figure 3f). Therefore, our data indicate that upregulation of PSMA5 has a critical role in carboplatin plus thioridazine-mediated apoptosis by downregulating expression of c-FLIP and Mcl-1.
Previous studies reported that the Nrf2/ARE signaling pathway is associated with the regulation of PSMA5 expression.28 Therefore, we investigated whether the Nrf2/ARE pathway is associated with PSMA5 expression in carboplatin plus thioridazine-treated cells. As shown in Figure 4a, carboplatin plus thioridazine induced upregulation of Nrf2 expression. Furthermore, nuclear translocation of Nrf2 is induced within 1h and increased up to 6h after carboplatin plus thioridazine treatment (Figure 4b). Combined treatment with carboplatin plus thioridazine induced the transcriptional activity of ARE (Figure 4c). To identify the importance of Nrf2/ARE signaling on carboplatin plus thioridazine-induced apoptosis, cells were treated with Nrf2 siRNA. Downregulation of Nrf2 expression by siRNA inhibited apoptotic cell death and upregulated PSMA5 expression (Figure 4d). Therefore, these data suggest that the combined treatment triggers upregulation of PSMA5 expression in an Nrf2/ARE signaling pathway-dependent manner.
As the Nrf2/ARE signaling pathway is activated by reactive oxygen species (ROS) production,32 we investigated whether combined treatment with carboplatin and thioridazine induces ROS production. Combined treatment with carboplatin and thioridazine induced ROS production within 1h (Figure 5a). In addition, we determined intracellular ROS by measuring the expression level of peroxiredoxin (Prx)-SO3. As shown in Figure 5b, peroxiredoxin (Prx)-SO3 was detected within 1h in carboplatin plus thioridazine-treated cells. Next, we investigated whether ROS are involved in the activation of Nrf2/ARE signaling. We found that ROS scavengers (N-acetylcysteine (NAC), glutathione-ethyl-ester, and trolox) inhibited the nuclear translocation of Nrf2 as well as ARE transcriptional activity in carboplatin plus thioridazine-treated cells (Figure 5c and d). The carboplatin plus thioridazine-induced PSMA5 promoter activity was also reduced by ROS scavengers (Figure 5e). Furthermore, ROS scavengers inhibited apoptotic cell death, downregulated c-FLIP and Mcl-1 expression, and upregulated PSMA5 expression in carboplatin plus thioridazine-treated cells (Figure 5f). Therefore, our results suggest that ROS have a critical role in carboplatin plus thioridazine-induced apoptosis.
As shown in Figure 5f, ROS have an important role in apoptosis induced by carboplatin plus thioridazine. Therefore, we investigated the source of ROS production induced by carboplatin plus thioridazine. ROS are mainly produced by NADPH oxidase and the mitochondrial electron transport chain.33 Cells were treated with NADPH oxidase inhibitors (diphenyleneiodonium (DPI) and apocynin) and a mitochondrial complex I inhibitor (rotenone).34, 35 Rotenone reduced carboplatin plus thioridazine-induced apoptotic cell death and cleavage of PARP, but DPI and apocynin did not (Figure 6a). In addition, rotenone reversed the upregulation of Nrf2 and PSMA5 expression and downregulated c-FLIP and Mcl-1 expression (Figure 6a). As shown in Figure 6b, combined treatment with carboplatin and thioridazine induced mitochondrial ROS within 1h. Carboplatin alone or thioridazine alone did not significantly increase ROS production at the concentrations used in this study. However, the combined treatment markedly produced ROS (Figure 6c). To confirm the importance of mitochondrial ROS, we used a specific mitochondrial superoxide scavenger, Mito-TEMPO. Mito-TEMPO markedly reduced apoptosis and the cleavage of PARP in a dose-dependent manner (Figure 6d). Upregulation of Nrf2 and PSMA5 and downregulation of c-FLIP and Mcl-1 were also reversed by Mtio-TEMPO treatment in carboplatin and thioridazine-treated cells (Figure 6d). Therefore, our data suggest that mitochondrial ROS have a critical role in carboplatin and thioridazine-induced apoptosis.
We next investigated the effect of carboplatin plus thioridazine on apoptosis in other cancer cells, including human breast carcinoma (MDA-MB231) and glioma (U87MG) cells. We found that combined treatment with carboplatin and thioridazine induced apoptotic cell death and cleavage of PARP in MDA-MB231 and U87MG cells (Figure 7a and b). Furthermore, carboplatin plus thioridazine induced upregulation of Nrf2 and PSMA5 expression and downregulation of c-FLIP and Mcl-1 expression (Figure 7a and b). By contrast, combined treatment with carboplatin and thioridazine did not induce morphological changes or apoptosis in normal human mesangial cells and normal human umbilical vein cells (EA.hy926) (Figure 7c and d).
In this study, we demonstrated that carboplatin plus thioridazine induces apoptosis in cancer cells, but not in normal cells. Combined treatment with carboplatin and thioridazine downregulated c-FLIP and Mcl-1 expression at the post-translational level in a proteasome-dependent manner. Along with the augmentation of proteasome activity, mitochondrial ROS activated the Nrf2/ARE signaling pathway and induced upregulation of PSMA5 expression in carboplatin plus thioridazine-treated cells.
Multiple mechanisms are involved in the anticancer activity of thioridazine. First, thioridazine inhibits PI3K/Akt signaling, which is important for cancer cell survival. Thioridazine inhibits cell viability and induces cell death through inhibition of the PI3K/Akt signaling pathway in ovarian cancer and in cervical and endometrial cancer cells.11, 12 In addition, thioridazine inhibits angiogenesis and tumor growth in ovarian cancer xenografts by inhibiting PI3K/Akt signaling.17 In our study, thioridazine also inhibited Akt phosphorylation (Supplementary Figure S1a). However, PI3K/Akt inhibitors (LY294002 and wortmanin) plus carboplatin did not induce apoptosis in head and neck cancer cells (Supplementary Figure S1b). Furthermore, both PI3K/Akt inhibitors had no effect on the downregulation of c-FLIP and Mcl-1 expression (Supplementary Figure S1b). Therefore, the anticancer effects of thioridazine are independent of the inhibition of the PI3K/Akt signaling pathways in head and neck cancer AMC-HN4 cells. Next, upregulation of ROS by thioridazine treatment also has a critical a role on the anticancer effect. Min et al.25 reported that thioridazine inhibited Mcl-1 and c-FLIP expression in a ROS-dependent manner, resulting in induction of apoptosis in TRAIL-treated human renal carcinoma Caki cells. However, thioridazine alone did not increase intracellular ROS levels (Figure 6c) and had no effect on the downregulation of c-FLIP and Mcl-1 expression (Figure 1g). Interestingly, a high concentration of carboplatin (>50μM) induced ROS production in cardiomyocytes,36 AMC-HN3 cells,37 and human laryngeal carcinoma cells.38 However, a low concentration of carboplatin (200nM) did not increase ROS production in our experiment. In addition, Rodrigues et al.39 reported that thioridazine interacts with the membrane of mitochondria, acquiring antioxidant activity. By contrast, 10μM thioridazine induced ROS production in Caki cells. However, 10μM thioridazine had no effect on ROS production in AMC-HN4 cells. These effects of thioridazine on ROS production may result from the different cellular ROS statuses and cell contexts. Although thioridazine alone did not induce ROS production, combined treatment with carboplatin and thioridazine induced apoptosis by downregulating the expression of c-FLIP and Mcl-1 in a ROS-dependent manner. Finally, thioridazine inhibits the focal adhesion kinase (FAK) and Src signaling pathway. In ovarian cancer cells, thioridazine inhibits VEGF-induced angiogenesis by inhibiting FAK and Src phosphorylation.18 However, identification of the anticancer molecular mechanism of thioridazine requires further study.
When anticancer drugs induce apoptosis in cancer cells, the expression of apoptosis-related proteins is often regulated at the post-translational level.25, 40 Protein degradation is mainly regulated by the ubiquitin-proteasomal or lysosomal pathways. In this studies, combined treatment with carboplatin and thioridazine induced proteasome activity (Figure 3b), followed by downregulation of c-FLIP and Mcl-1 expression (Figure 3a). When proteins are degraded at the post-translational level, there are critical two steps: (1) augmentation of proteasome activity. In our study, combined treatment with carboplatin and thioridazine markedly increased proteasome activity. For the augmentation of proteasome activity, carboplatin plus thioridazine upregulated PSMA5 expression at the transcriptional level, which is a protein that has a 20S proteasome catalytic core (Figure 3e). In previous studies, upregulation of the proteasome subunit was shown to be regulated by the Nrf2/ARE signaling pathways.28, 41 Combined treatment with carboplatin and thioridazine induced translocation of Nrf2 into the nucleus and then increased ARE transcriptional activity (Figure 4b and c). Downregulation of Nrf2 by siRNA inhibited upregulation of PSMA5 expression (Figure 4d). Interestingly, downregulation of PSMA5 expression by siRNA blocked augmentation of proteasome activity in carboplatin plus thioridazine-treated cells (Supplementary Figure S2). Therefore, upregulation of PSMA5 has a critical role on augmentation of proteasome activity. (2) upregulation of specific E3 ligase expression. As E3 ligase attaches ubiquitin to target proteins, protein degradation by the ubiquitin-proteasome system has high specificity. For example, four E3 ligases of Mcl-1 are known, including Mcl-1 ubiquitin ligase E3,30 beta transducin-containing protein (β-TrCP),42 F-box and WD repeat domain-containing 7,43 and Tripartite motif containing 17 (Trim17).44 Casitas B-lineage lymphoma (Cbl),45 and Itch46 work as an E3 ligase of c-FLIP. We also investigated the E3 ligase expression of c-FLIP and Mcl-1. However, combined treatment with carboplatin and thioridazine did not change E3 ligase expression of β-TrCP, Cbl, and Itch (Supplementary Figure S3). Further investigation is required to determine whether other E3 ligases or unknown E3 ligases might be involved in the degradation of c-FLIP and Mcl-1 expression.
Collectively, these results suggest that carboplatin plus thioridazine induces apoptosis in human head and neck cancer cells. The augmentation of proteasome activity by mitochondrial ROS-mediated PSMA5 expression induced downregulation of c-FLIP and Mcl-1 expression in carboplatin plus thioridazine-treated cells. Therefore, the combined modality approach with a low concentration of carboplatin and thioridazine may reduce the occurrence of unexpected side effects and improve the drug's anticancer effects.
Human head and neck cancer AMC-HN4 cells were obtained from Asan Medical Center. MDA-MB-231, U87MG, and EA.hy926 cells were purchased from the American Type Culture Collection (Manassas, VA, USA). Primary cultured human mesangial cells (Cryo NHMC) were purchased from Clonetics (San Diego, CA, USA). The cells were cultured in Dulbecco's modified Eagle's medium that contained 10% fetal bovine serum, 20mM Hepes buffer, and 100μg/ml gentamicin. The PCR primers were purchased from Macrogen, Inc. (Seoul, Korea), and the other chemicals were purchased from Sigma (St. Louis, MO, USA). NAC and Trolox were obtained from Calbiochem (San Diego, CA, USA). The anti-Bcl-2, anti-Bcl-xL, anti-Mcl-1, anti-XIAP, anti-Nrf2, and anti-PARP antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-cleaved caspase-3 and anti-cIAP1 antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). The anti-pro-caspase-3 and anti-c-FLIP antibodies was obtained from ALEXIS Corporation (San Diego, CA, USA). The anti-PSMA5 antibody was purchased from Cell Signaling Technology. The anti-peroxiredoxin-SO3 antibody was purchased from AbFRONTIER (Seoul, Korea). The anti-actin antibody was obtained from Sigma. The human Mcl-1 and c-FLIP expression vectors were constructed as described previously.47, 48
For flow cytometry, the cells were resuspended in 100μl of phosphate-buffered saline (PBS), and 200μl of 95% ethanol was added while the cells were being vortexed. Then, the cells were incubated at 4°C for 1h, washed with PBS, resuspended in 250μl of 1.12% sodium citrate buffer (pH 8.4) with 12.5μg of RNase and incubated for an additional 30min at 37°C. The cellular DNA was then stained by adding 250μl of a propidium iodide solution (50μg/ml) to the cells for 30min at room temperature. The stained cells were analyzed by fluorescent-activated cell sorting on a FACScan flow cytometer to determine the relative DNA content, which was based on the red fluorescence intensity. We provide the FACS plots in Supplementary Figure S4–S6.
For the western blot experiments, the cells were washed with cold PBS and lysed on ice in modified RIPA buffer (50mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150mM NaCl, 1mM Na3VO4, and 1mM NaF) containing protease inhibitors (100μM phenylmethylsulfonyl fluoride, 10μg/ml leupeptin, 10μg/ml pepstatin, and 2mM EDTA). The lysates were centrifuged at 10000 × g for 10min at 4°C, and the supernatant fractions were collected. The proteins were separated by SDS-PAGE electrophoresis and transferred to Immobilon-P membranes. The specific proteins were detected using an enhanced chemiluminescence western blotting kit according to the manufacturer's instructions.
The XTT assay was employed to measure cell viability using a WelCount Cell Viability Assay Kit (WelGENE, Daegu, Korea). In brief, the reagent was added to each well and was then measured with a multi-well plate reader (at 450nm/690nm).
To examine the cellular nuclei, the cells were fixed with 1% paraformaldehyde on glass slides for 30min at room temperature. After fixation, the cells were washed with PBS and a 300nM DAPI solution (Roche, Mannheim, Germany) was added to the fixed cells for 5min. After the nuclei were stained, the cells were examined by fluorescence microscopy.
A cell death detection ELISA plus kit (Boerhringer Mannheim; Indianapolis, IN, USA) was used to determine the level of apoptosis by detecting fragmented DNA within the nuclei of thioridazine-treated cells, carboplatin-treated cells, or cells that were treated with a combination of carboplatin and thioridazine. In brief, each culture plate was centrifuged for 10min at 200 × g, the supernatant was removed, and the cell pellet was lysed for 30min. Then, the plate was centrifuged again at 200 × g for 10min and the supernatant, which contained the cytoplasmic histone-associated DNA fragments, was collected and incubated with an immobilized anti-histone antibody. The reaction products were incubated with a peroxidase substrate for 5min and were measured by spectrophotometry at 405 and 490nm (reference wavelength) with a microplate reader. The signals in the wells containing the substrate alone were subtracted as the background.
To evaluate the DEVDase activity, cell lysates were prepared after their respective treatments with carboplatin in the presence or absence of thioridazine. Assays were performed in 96-well microtiter plates by incubating 20μg of the cell lysates in 100μl of reaction buffer (1% NP-40, 20mM Tris-HCl, pH 7.5, 137mM NaCl, 10% glycerol) containing a caspase substrate (Asp-Glu-Val-Asp-chromophore-p-nitroanilide (DVAD-pNA)) at 5μM. The lysates were incubated at 37°C for 2h. Thereafter, the absorbance at 405nm was measured with a spectrophotometer.
Total RNA was isolated using the TriZol reagent (Life Technologies; Gaithersburg, MD, USA), and the cDNA was prepared using M-MLV reverse transcriptase (Gibco-BRL; Gaithersburg, MD, USA) according to the manufacturers' instructions.49, 50 The following primers were used for the amplification of human c-FLIP, Mcl-1, PSMA5, and actin: c-FLIP (sense) 5′-CGGACTATAGAGTGCTGATGG-3′ and (antisense) 5′-GATTATCAGGCAGATTCCTAG-3′ Mcl-1 (sense) 5′-GCGACTGGCAAAGCTTGGCCTCAA-3′ and (antisense) 5′-GTTACAGCTTGGATCCCAACTGCA-3′ PSMA5 (sense) 5′-CTTGCAAGAAGTTTATCACAAGTCT-3′ and (antisense) 5′-GAAATTCTGGCCAGGCTGC-3′ and actin (sense) 5′-GGCATCGTCACCAACTGGGAC-3′, and (antisense) 5′-CGATTTCCCGCTCGGCCGTGG-3′. PCR amplification was carried out using the following cycling conditions: 94°C for 3min followed by 17 (actin) or 23 cycles (c-FLIP, and Mcl-1, and PSMA5) of 94°C for 45s; 58°C for 45s; 72°C for 1min; and a final extension at 72°C for 10min. The amplified products were separated by electrophoresis on a 1.5% agarose gel and detected under UV light.
The chymotryptic proteasome activities were measured with Suc-LLVY-AMC (chymotryptic substrate, Biomol International, Plymouth Meeting, PA, USA). The cells were collected, washed with PBS and lysed. A mixture containing 1μg of protein from the cell lysate in 100mM Tris-HCl (pH 8.0), 10mM MgCl2, and 2mM ATP was incubated at 37°C for 30min with 50μM Suc-LLVY-AMC. Enzyme activity was measured with a fluorometric plate reader at an excitation wavelength of 380nm and an emission wavelength of 440nm.
Transient transfection was performed in six-well plates. One day before transfection, AMC-HN4 cells were plated at ~6080% confluence. The PSMA5/-277-luc and ARE-luc plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). To assess promoter-driven expression of the luciferase gene, cells were collected and disrupted by sonication in lysis buffer (25mM Tris-phosphate, pH 7.8, 2mM EDTA, 1% Triton X-100, and 10% glycerol), and aliquots of the supernatant were used to analyze the luciferase activity according to the manufacturer's instructions (Promega, Madison, WI, USA).
Following the required treatments, AMC-HN4 cells were trypsinized and suspended in buffer A (10mM HEPES at pH 7.9, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 1mM DTT, 0.5mM PMSF). After incubation on ice for 30min, the cells were centrifuged at 2500rpm for 3min to obtain a nuclear pellet. The supernatant fractions were collected as the cytosol extract. Buffer C (20mM HEPES at pH 7.9, 0.4M NaCl, 1mM EDTA, 1mM DTT, and 1mM PMSF) was added, followed by a rotation for 30min at 4°C. The resulting lysates were centrifuged at 12000rpm at 4°C for 5min. The supernatant fractions were collected as the nuclear extract.
The GFP (control), Nrf2, and PSMA5 small interfering RNA (siRNA) duplexes used in this study were purchased from Santa Cruz Biotechnology. The cells were transfected with siRNA using Oligofectamine Reagent (Invitrogen, Carlsbad, California, USA) according to the manufacturer's recommendations.
Intracellular accumulation of ROS was determined using the fluorescent probes 2′, 7′-dichlorodihydrofluorescein diacetate (H2DCFDA) and Mitosox Red. The AMC-HN4 cells were treated with carboplatin plus thioridazine, and then, the cells were stained with the H2DCFDA fluorescent dye or Mitosox Red for an additional 10min, followed by trypsinization and resuspension in PBS. The fluorescence was measured at specific time intervals with a flow cytometer (Becton–Dickinson; Franklin Lakes, NJ, USA) or fluorescence microscope (Zeiss, NY, USA).
The data were analyzed using one-way analysis of variance and post hoc comparisons (Student–Newman–Keuls) using the Statistical Package for Social Sciences 22.0 software (SPSS Inc.; Chicago, IL, USA).
This work was supported by an NRF grant funded by the Korea Government (MSIP) (2014R1A5A2010008).
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
Edited by M Daugaard
The authors declare no conflict of interest.